Oncogenes and tumor suppressor genes in malignant mesothelioma

Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies

Volumn , Issue , 2005, Pages 124-140

  Kratzke, Robert A ^a,b   Gazdar, Adi F ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959225066     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-28274-2_8     Document Type: Chapter

References (91)

1. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.
2. Baser ME, De Rienzo A, Altomare D, et al. Neurofibromatosis 2 and malignant mesothelioma. Neurology 2002;59:290-291.
3. Kane MJ, Chahinian AP, Holland JF. Malignant mesothelioma in young adults. Cancer 1990;65:1449-1455.
4. Risberg B, Nickels J, Wagermark J. Familial clustering of malignant mesothelioma. Cancer 1980;45:2422-2427.
5. Hammar SP, Bockus D, Remington F, Freidman S, LaZerte G. Familial mesothelioma: a report of two families. Hum Pathol 1989;20:107-112.
6. Musti M, Cavone D, Aalto Y, Scattone A, Serio G, Knuutila S. A cluster of familial malignant mesothelioma with del (9p) as the sole chromosomal anomaly. Cancer Genet Cytogenet 2002;138:73-76.
7. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Geneticsusceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357:444-445.
8. Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1989;1:148-154.
9. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993;53:4349-4355.
10. Cheng JQ, Jhanwar SC, Lu YY, Testa JR. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 1993;53:4761-4763.
11. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
12. Kratzke RA, Otterson GA, Lincoln CE, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87:1870-1875.
13. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511.
14. Friend SH, Horowitz JM, Gerber MR, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encdoded protein. Proc Natl Acad Sci USA 1987;84:9059-9063.
15. Kratzke RA, Shimizu E, Kaye FJ. Oncogenes in human lung cancer. Cancer Treat Res 1992;63:61-85.
16. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
17. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 1995;87:756-761.
18. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415-3420.
19. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. Oncogene 1994;9:3375-3378.
20. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511-515.
21. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-5551.
22. Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 2001;32:27-38.
23. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-2964.
24. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990.
25. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-5730.
26. Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16 (INK4a) expression in malignant mesothelioma by methylation. Lung Cancer 2002;38:131-136.
27. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16 (INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002;23:1127-1130.
28. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998;16:3087-3095.
29. Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 2000;7:1421-1425.
30. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-659.
31. Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14 (ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000;92:636-641.
32. Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma (review). Int J Oncol 1999;14:181-188.
33. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
34. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001;38:535-541.
35. Bongiovanni M, Cassoni P, De Giuli P, et al. p27 (kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001;92:1245-1250.
36. Beer TW. Immunohistochemical MIB-1 and p27 as prognostic factors in pleural mesothelioma. Pathol Res Pract 2001;197:859.
37. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999;59:684-688.
38. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-945.
39. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27 (kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385.
40. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 1997;57:1259-1263.
41. Isik R, Metintas M, Gibbs AR, et al. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir Med 2001;95:588-593.
42. Baldi A, Groeger AM, Esposito V, et al. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax 2002;57:353-356.
43. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
44. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet 2000;37:897-904.
45. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-521.
46. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
47. Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-1231.
48. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92:10854-10858.
49. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
50. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998;157:1093-1097.
51. Liu BC, Fu DC, Miao Q, Wang HH, You BR. p53 gene mutations in asbestos associated cancers. Biomed Environ Sci 1998;11:226-232.
52. Mayall FG, Jacobson G, Wilkins R. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. J Clin Pathol 1999;52:291-293.
53. Ni Z, Liu Y, Keshava N, Zhou G, Whong W, Ong T. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 2000;468:87-92.
54. Pass HI, Stevens EJ, Oie H, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995;59:835-844.
55. Unfried K, Roller M, Pott F, Friemann J, Dehnen W. Fiber-specific molecular features of tumors induced in rat peritoneum. Environ Health Perspect 1997;105 S: 1103-1108.
56. Kleymenova EV, Horesovsky G, Pylev LN, Everitt J. Mesotheliomas induced in rats by the fibrous mineral erionite are independent from p53 alterations. Cancer Lett 1999;147:55-61.
57. Vaslet CA, Messier NJ, Kane AB. Accelerated progression of asbestosinduced mesotheliomas in heterozygous p53+/-mice. Toxicol Sci 2002;68:331-338.
58. Marsella JM, Liu BL, Vaslet CA, Kane AB. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect 1997;105(suppl 5):1069-1072.
59. Cote RJ, Jhanwar SC, Novick S, Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 1991;51:5410-5416.
60. Creaney J, McLaren BM, Stevenson S, et al. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 2001;84:52-56.
61. Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M, Procopio A. Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000;5:591-596.
62. Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14 (ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001;61:5959-5963.
63. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 1997;48:267-281.
64. Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002;62:5897-5901.
65. Shivapurkar N, Toyooka S, Eby MT, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002;1:65-69.
66. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 1999;5:3508-3515.
67. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002;123:1191-1198.
68. Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl downregulation in mesothelioma. Cancer Gene Ther 2001;8:547-554.
69. Pataer A, Smythe WR, Yu R, et al. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001;121:61-67.
70. van Noesel MM, van Bezouw S, Salomons GS, et al. Tumor-specific downregulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002;62:2157-2161.
71. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem 2002;383:907-914.
72. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001;98:7504-7509.
73. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001;20:3563-3567.
74. Toyooka S, Carbone M, Toyooka KO, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340-4344.
75. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-520.
76. Weissman BE, Saxon PJ, Pasquale SR, Jones GR, Geiser AG, Stanbridge EJ. Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science 1987;236:175-180.
77. Yang Y, Gubler MC, Beaufils H. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy. Nephron 2002;91:416-423.
78. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-225.
79. Park S, Schalling M, Bernard A, et al. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993;4:415-420.
80. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-356.
81. Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-1320.
82. Gubler MC. WT1, a multiform protein. Contribution of genetic models to the understanding of its various functions. J Am Soc Nephrol 2002;13:2192-2194.
83. Kleymenova EV, Yuan X, LaBate ME, Walker CL. Identification of a tumorspecific methylation site in the Wilms tumor suppressor gene. Oncogene 1998;16:713-720.
84. Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat Rev Cancer 2002;2:957-964.
85. Bocchetta M, Di Resta I, Powers A, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 2000;97:10214-10219.
86. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 2001;11:23-30.
87. Carbone M, Rizzo P, Grimley PM, et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 1997;3:908-912.
88. Foddis R, De Rienzo A, Broccoli D, et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002;21:1434-1442.
89. Zanella CL, Timblin CR, Cummins A, et al. Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fos and apoptosis. Am J Physiol 1999;277:L684-693.
90. Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26:189-193.
91. Bocchetta M, Miele L, Pass HI, Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 2003;22:81-89.